Trial Profile
A Retrospective, Longitudinal Multi-Center Study of Radium-223 in Patients With Metastatic Castration-Resistant Prostate Cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Radium 223 chloride (Primary) ; Abiraterone; Cabazitaxel; Docetaxel; Enzalutamide
- Indications Bone metastases; Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Bayer
- 18 Nov 2019 Status changed from active, no longer recruiting to completed.
- 22 Aug 2019 Planned End Date changed from 15 Aug 2019 to 31 Oct 2019.
- 22 Aug 2019 Planned primary completion date changed from 15 Aug 2019 to 31 Oct 2019.